Disease stage-specific atrophy markers in Alzheimer’s disease
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Structural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer’s disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases.
METHODS
We included 363 older adults; healthy controls (HC) who were negative or positive for amyloid-beta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years.
RESULTS
Accelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage.
DISCUSSION
With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
